The New England Journal of Medicine

Official Account https://www.nejm.org/ nejm

Overview

Pelacarsen and Cardiovascular Outcomes in Patients with High Lipoprotein(a)

Nov 7, 2026DOI: 10.1056/nejmoa2610159Original ArticleNEJM

Written by: Leslie Cho, M.D.Stephen J. Nicholls, M.B., B.S.Seth Frndak, Ph.D.Kathy Wolski, M.P.H.Børge G. Nordestgaard, M.D.Brian Manning, Pharm.D.Eran Leitersdorf, M.D.Ulf Landmesser, M.D.Venu Menon, M.D.Jackie McCluskey, R.N.Michael J. Blaha, M.D.Ryuichi Morishita, M.D.A. Michael Lincoff, M.D.Ziqiang Zhao, Ph.D.Jing Wang, Ph.D.Raul D. Santos, M.D.Ioanna Gouni-Berthold, M.D.Sotirios Tsimikas, M.D.Anastasia Lesogor, M.D.Hui Cao, M.D.Steven E. Nissen, M.D.

Summary

Among patients with cardiovascular disease and high lipoprotein(a) levels, pelacarsen lowered the lipoprotein(a) level, but the risk of major cardiovascular events was similar with pelacarsen and placebo.